STANFORD UNIVERSITY

Ridge Biotechnologies emerged from stealth with an oversubscribed $25 million seed financing led by Sutter Hill Ventures to advance AI-enabled enzyme and targeted drug design for precision medicines.

Stanford University has been awarded a double-digit million dollar NIH grant to conduct a Phase II trial of Tiprelestat for pulmonary arterial hypertension, with patient enrollment expected to begin in mid-2026.

4DMedical has received FDA 510(k) clearance for CT:VQ, the world's first non-contrast CT-based ventilation-perfusion imaging software that eliminates the need for radioactive tracers.

Foresight Diagnostics and Roche have entered a limited licensing agreement for PhasED-Seq technology, resolving litigation between the parties with all claims dismissed with prejudice.

Larkspur Biosciences announced the discovery of LRK-4189, a first-in-class degrader targeting the lipid kinase PIP4K2C for treating microsatellite stable colorectal cancer.

Multiply Labs' robotic biomanufacturing cluster achieves a 74% cost reduction in cell therapy production through collaborative robot arms from Universal Robots, as demonstrated in peer-reviewed studies with UCSF.

Three prominent clinical trials testing Paxlovid and monoclonal antibodies for Long COVID failed to show significant health improvements compared to placebo groups.

Percheron Therapeutics released preclinical data published in Cancer Research showing HMBD-002 effectively blocked tumor growth in triple-negative breast cancer mouse models with statistically significant results (p < 0.0001).

Stanford Medicine researchers found that ibogaine treatment led to an 88% reduction in PTSD symptoms and 87% reduction in depression symptoms in 30 special operations veterans with traumatic brain injury.

Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.